Invention Grant
US09561265B2 KIF20A epitope peptides for TH1 cells and vaccines containing the same
有权
用于TH1细胞的KIF20A表位肽和含有它们的疫苗
- Patent Title: KIF20A epitope peptides for TH1 cells and vaccines containing the same
- Patent Title (中): 用于TH1细胞的KIF20A表位肽和含有它们的疫苗
-
Application No.: US14413403Application Date: 2013-07-09
-
Publication No.: US09561265B2Publication Date: 2017-02-07
- Inventor: Yasuharu Nishimura , Yusuke Tomita , Ryuji Osawa
- Applicant: ONCOTHERAPY SCIENCE, INC.
- Applicant Address: JP Kanagawa
- Assignee: OncoTherapy Science, Inc.
- Current Assignee: OncoTherapy Science, Inc.
- Current Assignee Address: JP Kanagawa
- Agency: Kilpatrick Townsend & Stockton LLP
- International Application: PCT/JP2013/004248 WO 20130709
- International Announcement: WO2014/010231 WO 20140116
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K39/00 ; C12N5/0783 ; C12N9/14 ; C07K16/28 ; C07K16/30 ; C07K7/06 ; C07K7/08 ; C07K14/00

Abstract:
Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
Public/Granted literature
- US20150190489A1 KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME Public/Granted day:2015-07-09
Information query
IPC分类: